Holder evidence
50
SEC ownership of Crinetics Pharmaceuticals, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001658247.
Lead holder
FMR LLC
13D/G signal
FMR LLC
Latest evidence
31 Mar 2026
- CIK
- 0001658247
- Symbol
- CRNX on Nasdaq
- Location
- San Diego, CA
- SEC evidence mix
- 13F and 13D/G
- Lead holder
- FMR LLC
- Latest large-stake holder
- FMR LLC
- Latest evidence date
- 31 Mar 2026
Issuer identity
Ownership snapshot
Ownership snapshot
Top shareholders of Crinetics Pharmaceuticals, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Lead holder
FMR LLC
13D/G signal
FMR LLC
Evidence rows
50
Latest as of
31 Mar 2026
13F
13D/G
Lead comparable stake: 15%
13D/G row: FMR LLC
Showing 1-8 of 50 holder rows.
Rank 1 holder
FMR LLC
13F
13D/G
- Ownership
- 15%
- Position
- $572.4M
Rank 2 holder
Farallon Capital Partners, L.P.
13D/G
- Ownership
- 8.5%
- Position
- $373.52M
Rank 3 holder
WELLINGTON MANAGEMENT GROUP LLP
13D/G
13F
- Ownership
- 7.8%
- Position
- $321.72M
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FMR LLC |
13F
13D/G
Company
|
15%
from 13D/G
|
$572,395,895
15,759,799 shares
|
— | 31 Mar 2026 |
| Farallon Capital Partners, L.P. |
13D/G
Dapice Joshua J.
|
8.5%
|
$373,521,762
8,024,098 shares
|
+$111,673,450 | 31 Dec 2025 |
| WELLINGTON MANAGEMENT GROUP LLP |
13D/G
13F
Company
|
7.8%
|
$321,720,126
8,157,204 shares
|
-$8,865,599 | 31 Mar 2026 |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13D/G
13F
Company
|
6.1%
|
$252,255,164
6,395,922 shares
|
$0 | 31 Mar 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13D/G
13F
Vanguard Capital Management · Company
|
5.2%
|
$197,604,263
5,440,646 shares
|
$0 | 31 Mar 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13D/G
13F
T. Rowe Price Associates, Inc. · Company
|
5.1%
|
$211,201,634
5,355,011 shares
|
$0 | 31 Mar 2026 |
| BlackRock, Inc. |
13F
Company
|
8.1%
|
$307,950,573
8,478,815 shares
|
— | 31 Mar 2026 |
| FARALLON CAPITAL MANAGEMENT LLC |
13F
Company
|
7.9%
|
$302,839,719
8,338,098 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$11,655,322.
Buys
$0
Insiders: 0
Sells
$11,655,322
Insiders: 9
Net
-$11,655,322
Shares: -318,855
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 318,855
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 142,380 | $0 | $5,569,647 | -$5,569,647 |
| 3-6 | 0 | 7,500 | $0 | $362,600 | -$362,600 |
| 6-9 | 0 | 35,000 | $0 | $1,478,862 | -$1,478,862 |
| 9-12 | 0 | 133,975 | $0 | $4,244,214 | -$4,244,214 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-18 of 18 reporting-owner rows connected to Crinetics Pharmaceuticals, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
18
Lead holder
PERCEPTIVE ADVISORS LLC
Net 12M change
-$11,655,323
Latest report
08 Apr 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 10%+ Owner | $200,336,855 | Mixed | 18 Apr 2022 | ||
| Richard Scott Struthers | President & CEO, Director | $58,407,741 | -$1,001,513 | -1.7% | Mixed | 16 Mar 2026 |
| Ajay Madan | Chief Development Officer | $7,783,510 | Mixed | 28 Feb 2022 | ||
| Stephen F. Betz | Chief Scientific Officer | $5,178,304 | -$3,538,487 | -41% | Filing P/S | 16 Mar 2026 |
| Jeff E. Knight | Chief Dev. & Operating Officer | $4,222,088 | -$3,785,448 | -47% | Filing P/S | 08 Apr 2026 |
| Wendall Wierenga | Director | $3,869,984 | Mixed | 11 Jun 2025 | ||
| Tobin Schilke | Chief Financial Officer | $3,099,060 | -$266,305 | -7.9% | Filing P/S | 03 Mar 2026 |
| Dana Pizzuti | Chief Med and Dev Officer | $3,009,001 | -$1,910,299 | -39% | Filing P/S | 01 Dec 2025 |
| Isabel Kalofonos | Chief Commercial Officer | $1,939,905 | -$137,500 | -6.6% | Mixed | 23 Feb 2026 |
| Marc Wilson | Cfo | $1,671,244 | Mixed | 31 Dec 2024 | ||
| Alan Seth Krasner | Chief Medical Officer | $1,626,857 | Mixed | 17 Oct 2023 | ||
| James Hassard | Chief Commercial Officer | $1,289,737 | Filing P/S | 05 Jul 2024 | ||
| Matthew K. Fust | Director | $1,021,911 | -$716,000 | -41% | Filing P/S | 26 Sep 2025 |
| Coelho Rogerio Vivaldi | Director | $599,351 | -$180,761 | -23% | Filing P/S | 12 Mar 2026 |
| Camille L. Bedrosian | Director | $543,116 | Mixed | 11 Jun 2025 | ||
| Weston Nichols | Director | $543,116 | Mixed | 11 Jun 2025 | ||
| Caren Deardorf | Director | $543,116 | Mixed | 11 Jun 2025 | ||
| Stephanie Okey | Director | $527,611 | -$119,010 | -18% | Filing P/S | 03 Mar 2026 |
Recent insider transactions for Crinetics Pharmaceuticals, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Reported value | Reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Jeff E. Knight | CRNX | Common Stock | Sale | -44.7% | $3,415,036 | $40.10 | -85,163 | 105,289 | 08 Apr 2026 | Direct |
| Jeff E. Knight | CRNX | Common Stock | Options Exercise | 70% | 78,434 | 190,452 | 08 Apr 2026 | Direct | ||
| Jeff E. Knight | CRNX | Stock Option (Right to Buy) | Options Exercise | -88.1% | -78,434 | 10,589 | 08 Apr 2026 | Direct | ||
| Jeff E. Knight | CRNX | Common Stock | Sale | -8.13% | $370,411 | $37.37 | -9,911 | 112,018 | 16 Mar 2026 | Direct |
| Stephen F. Betz | CRNX | Common Stock | Sale | -7.18% | $396,610 | $37.37 | -10,612 | 137,101 | 16 Mar 2026 | Direct |
| Richard Scott Struthers | CRNX | Common Stock | Sale | -5.15% | $821,513 | $37.37 | -21,981 | 404,778 | 16 Mar 2026 | Direct |
| Coelho Rogerio Vivaldi | CRNX | Common Stock | Sale | -23.5% | $180,761 | $36.15 | -5,000 | 16,300 | 12 Mar 2026 | Direct |
| Stephanie Okey | CRNX | Common Stock | Sale | -18.4% | $119,010 | $39.67 | -3,000 | 13,300 | 03 Mar 2026 | Direct |
| Tobin Schilke | CRNX | Common Stock | Sale | -7.91% | $266,305 | $39.67 | -6,713 | 78,121 | 03 Mar 2026 | Direct |
| Richard Scott Struthers | CRNX | Common Stock | Award | 17% | 62,000 | 426,759 | 23 Feb 2026 | Direct | ||
| Richard Scott Struthers | CRNX | Stock Option (Right to Buy) | Award | 228,000 | 228,000 | 23 Feb 2026 | Direct | |||
| Tobin Schilke | CRNX | Common Stock | Award | 60.6% | 32,000 | 84,834 | 23 Feb 2026 | Direct | ||
| Tobin Schilke | CRNX | Stock Option (Right to Buy) | Award | 50,000 | 50,000 | 23 Feb 2026 | Direct | |||
| Jeff E. Knight | CRNX | Common Stock | Award | 38.7% | 34,000 | 121,929 | 23 Feb 2026 | Direct | ||
| Jeff E. Knight | CRNX | Stock Option (Right to Buy) | Award | 55,000 | 55,000 | 23 Feb 2026 | Direct | |||
| Stephen F. Betz | CRNX | Common Stock | Award | 25.5% | 30,000 | 147,713 | 23 Feb 2026 | Direct | ||
| Stephen F. Betz | CRNX | Stock Option (Right to Buy) | Award | 47,000 | 47,000 | 23 Feb 2026 | Direct | |||
| Isabel Kalofonos | CRNX | Common Stock | Award | 4076.7% | 34,000 | 34,834 | 23 Feb 2026 | Direct | ||
| Isabel Kalofonos | CRNX | Stock Option (Right to Buy) | Award | 55,000 | 55,000 | 23 Feb 2026 | Direct | |||
| Isabel Kalofonos | CRNX | Common Stock | Sale | -75% | $137,500 | $55.00 | -2,500 | 834 | 05 Jan 2026 | Direct |
| Isabel Kalofonos | CRNX | Common Stock | Options Exercise | 299.8% | 2,500 | 3,334 | 05 Jan 2026 | Direct | ||
| Isabel Kalofonos | CRNX | Stock Option (Right to Buy) | Options Exercise | -2.5% | -2,500 | 97,500 | 05 Jan 2026 | Direct | ||
| Stephen F. Betz | CRNX | Common Stock | Options Exercise | 18% | 18,000 | 117,713 | 26 Dec 2025 | Direct | ||
| Stephen F. Betz | CRNX | Stock Option (Right to Buy) | Options Exercise | -16.6% | -18,000 | 90,514 | 26 Dec 2025 | Direct | ||
| Richard Scott Struthers | CRNX | Common Stock | Options Exercise | 14% | 44,742 | 364,759 | 18 Dec 2025 | Direct | ||
| Richard Scott Struthers | CRNX | Stock Option (Right to Buy) | Options Exercise | -100% | -44,742 | 0 | 18 Dec 2025 | Direct | ||
| Dana Pizzuti | CRNX | Common Stock | Sale | -6.96% | $225,100 | $45.02 | -5,000 | 66,837 | 01 Dec 2025 | Direct |
| Dana Pizzuti | CRNX | Common Stock | Options Exercise | 7.48% | 5,000 | 71,837 | 01 Dec 2025 | Direct | ||
| Dana Pizzuti | CRNX | Stock Option (Right to Buy) | Options Exercise | -6.75% | -5,000 | 69,042 | 01 Dec 2025 | Direct | ||
| Dana Pizzuti | CRNX | Common Stock | Sale | -7.02% | $213,312 | $42.66 | -5,000 | 66,270 | 03 Nov 2025 | Direct |
| Dana Pizzuti | CRNX | Common Stock | Options Exercise | 7.54% | 5,000 | 71,270 | 03 Nov 2025 | Direct | ||
| Dana Pizzuti | CRNX | Stock Option (Right to Buy) | Options Exercise | -6.33% | -5,000 | 74,042 | 03 Nov 2025 | Direct | ||
| Dana Pizzuti | CRNX | Common Stock | Sale | -7.02% | $209,050 | $41.81 | -5,000 | 66,270 | 01 Oct 2025 | Direct |
| Dana Pizzuti | CRNX | Common Stock | Options Exercise | 7.54% | 5,000 | 71,270 | 01 Oct 2025 | Direct | ||
| Dana Pizzuti | CRNX | Stock Option (Right to Buy) | Options Exercise | -5.95% | -5,000 | 79,042 | 01 Oct 2025 | Direct | ||
| Richard Scott Struthers | CRNX | Common Stock | Sale | -3.64% | $180,000 | $45.00 | -4,000 | 106,000 | 26 Sep 2025 | By Family Trust 2 |
| Matthew K. Fust | CRNX | Common Stock | Sale | -41.2% | $716,000 | $44.75 | -16,000 | 22,836 | 26 Sep 2025 | Direct |
| Matthew K. Fust | CRNX | Common Stock | Options Exercise | 34.7% | 10,000 | 38,836 | 26 Sep 2025 | Direct | ||
| Matthew K. Fust | CRNX | Stock Option (Right to Buy) | Options Exercise | -82.7% | -10,000 | 2,092 | 26 Sep 2025 | Direct | ||
| Dana Pizzuti | CRNX | Common Stock | Sale | -4.94% | $160,500 | $32.10 | -5,000 | 96,270 | 02 Sep 2025 | Direct |
| Dana Pizzuti | CRNX | Common Stock | Options Exercise | 5.19% | 5,000 | 101,270 | 02 Sep 2025 | Direct | ||
| Dana Pizzuti | CRNX | Stock Option (Right to Buy) | Options Exercise | -5.62% | -5,000 | 84,042 | 02 Sep 2025 | Direct | ||
| Dana Pizzuti | CRNX | Common Stock | Sale | -31.2% | $912,900 | $30.43 | -30,000 | 66,270 | 22 Aug 2025 | Direct |
| Dana Pizzuti | CRNX | Common Stock | Options Exercise | 45.3% | 30,000 | 96,270 | 22 Aug 2025 | Direct | ||
| Dana Pizzuti | CRNX | Stock Option (Right to Buy) | Options Exercise | -25.2% | -30,000 | 89,042 | 22 Aug 2025 | Direct | ||
| Dana Pizzuti | CRNX | Common Stock | Sale | -8.92% | $189,437 | $29.18 | -6,492 | 66,270 | 20 Aug 2025 | Direct |
| Stephen F. Betz | CRNX | Common Stock | Sale | -49.4% | $3,141,877 | $32.23 | -97,483 | 99,713 | 12 Jun 2025 | Direct |
| Stephen F. Betz | CRNX | Common Stock | Options Exercise | 80.9% | 88,170 | 197,196 | 12 Jun 2025 | Direct | ||
| Stephen F. Betz | CRNX | Stock Option (Right to Buy) | Options Exercise | -60.2% | -88,170 | 58,198 | 12 Jun 2025 | Direct | ||
| Caren Deardorf | CRNX | Common Stock | Award | 73.4% | 6,900 | 16,300 | 11 Jun 2025 | Direct |
* indicates a reported price that failed the local validity check.